Statistical Design and Considerations of a Phase 3 Basket Trial for Simultaneous Investigation of Multiple Tumor Types in One Study

References

• Barker, A. D., Sigman, C. C., Kelloff, G. J., Hylton, N. M., Berry, D. A., and Esserman, L. J. (2009), “I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy,” Clinical Pharmacology Therapy, 86, 97–100.
   Google Scholar
• Bauer, P., Koenig, F., Brannath, W., and Posch, M. (2010), “Selection and Bias—Two Hostile Brothers,” Statistics in Medicine, 29(1), 1–13. doi: 10.1002/sim.3716.
   Google Scholar
• Beckman, R. A., Antonijevic, Z., Kalamegham, R, and Chen, C. (in press), “Design for a Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker,” Clinical Pharmacology & Theraputics, forthcoming.
   Google Scholar
• Beckman, R. A., Clark, J., and Chen, C. (2011), “Integrating Predictive Biomarkers and Classifiers into Oncology Clinical Development Programmes,” Nature Review Drug Discovery,” 10, 735–749.
   Google Scholar
• Berry, D. A. (2015), “The Brave New World of Clinical Cancer Research: Adaptive Biomarker-Driven Trials Integrating Clinical Practice with Clinical Research,” Molecular Oncology, 9, 951–959.
   Google Scholar
• Berry, S. M., Broglio, K. R., Groshen, S., and Berry, D. A. (2013), “Bayesian Hierarchical Modeling of Patient Subpopulations: Efficient Designs of Phase II Oncology Clinical Trials,” Clinical Trials, 10, 720–734.
   Google Scholar
• Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., et al. (2011), “Improved Survival with Vemurafenib in Melanoma with V600E Mutation,” New England Journal of Medicine, 364, 2507–2516.
   Google Scholar
• Chen, C., and Beckman, R. A. (2009), “Optimal Cost-Effective Go-No Go Decisions in Late-Stage Oncology Drug Development,” Statistics in Biopharmaceutical Research, 1, 159–169.
   Google Scholar
• ——— (2014), “Maximizing Return on Socioeconomic Investment in Phase II Proof-of-Concept Trials,” Cancer Clinical Research, 20, 1730–1734.
   Google Scholar
• Chen, C., Sun, L., and Chih, C. (2013), “Evaluation of Early Efficacy Endpoints for Proof-of-concept Trials,” Journal of Biopharmaceutical Statistics, 23, 413–424.
   Google Scholar
• Demetri, G., Becker, R., Woodcock, J., Doroshow, J., Nisen, P., and Sommer, J. (2011), “Alternative Trial Designs Based on Tumor Genetics/Pathway Characteristics Instead of Histology,” in Issue Brief: Conference on Clinical Cancer Research, pp. 1–6. Available at http://www.focr.org/conference-clinical-cancer-research-2011
   Google Scholar
• Heinrich, M. C., Joensuu, H., Demetri, G. D., Corless, C. L., Apperley, J., Fletcher, J. A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., McKinley, A., Supple, S. G., Seymour, J., Di Scala, L., van Oosterom, A., Herrmann, R., Nikolova, Z., McArthur, A. G., and Imatinib Target Exploration Consortium Study B2225 (2008), “Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to be Associated with Imatinib-Sensitive Tyrosine Kinases,” Clinical Cancer Research, 14, 2717–2725.
   Google Scholar
• Herbst, R. S., Gandara, D. R., Hirsch, F. R., Redman, M. W., LeBlanc, M., Mack, O. C., et al. (2015) Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400, 21, 1514–1524.
   Google Scholar
• Kim, E. S., Herbst, R. S., Wistuba, II., Lee, J. J., Blumenschein, G. R., Jr., Tsao, A., et al. (2011), “The BATTLE Trial: Personalizing Therapy for Lung Cancer,” Cancer Discovery, 1, 44–53.
   Google Scholar
• Kopetz, S. (2013), “Right Drug for the Right Patient,” in Hurdles and the Path Forward in Colorectal Cancer, Chicago, IL: ASCO Educational Book. Available at http://meetinglibrary.asco.org/content/19-132
   Google Scholar
• Lacombe, D., Burocka, S., Bogaertsa, J., Schoeffskib, P., Golfinopoulosa, V., and Stuppa, R. (2014), “The Dream and Reality of Histology Agnostic Cancer Clinical Trials,” Molecular Oncology, 8, 1057–1063.
   Google Scholar
• Magnusson, B., and Turnbull, B. W. (2013), “Group Sequential Enrichment Design Incorporating Subgroup Selection,” Statistics in Medicine, 32, 2695–2714.
   Google Scholar
• McNeil, C. (2015), “NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era,” JNCI Journal National Cancer Institute, 107, djv193, doi:10.1093/jnci/djv193.
   Google Scholar
• Meador, C. B., Micheel, C. M., Levy, M. A., Lovly, C. M., Horn, L., Warner, J. L., Johnson, D. B., Zhao, Z., Anderson, I. A., Sosman, J. A., Vnencak-Jones, C. L., Dahlman, K. B., and Pao, W. (2014) “Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted therapies,” Clinical Cancer Research, 20, 2264–2275.
   Google Scholar
• Neuenschwander, B., Wandel, S., Roychoudhury, S., and Bailey, S. (2016) “Robust Exchangeability Designs for Early Phase Clinical Trials with Multiple Strata,” Pharmaceutical Statistics, 15, 123–134.
   Google Scholar
• Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., and Bernards, R. (2012), “Unresponsiveness of Colon Cancer to BRAF(V600E) Inhibition Through Feedback Activation of EGFR,” Nature, 483, 100–103.
   Google Scholar
• Sargent, D., Wieand, S., Haller, D. G., et al. (2005), “Disease-Free Survival (DFS) vs. Overall Survival (OS) as a Primary Endpoint for Adjuvant Colon Cancer Studies: Individual Patient Data From 20, 898 Patents on 18 Aandomized Trials,” Journal of Clinical Oncology, 23, 8664–8670.
   Google Scholar
• SAS/STAT® Software (1997), Changes and Enhancements Through Release 6.12, Cary, NC: SAS Institute Inc..
   Google Scholar
• Simon, R., Geyer, S., Subramanian, J., and Roychowdhury, S. (2016), “The Bayesian Basket Design for Genomic Variant-Driven Phase II Trials,” Seminars in Oncology, 43, 13–18.
   Google Scholar
• Sleijfer, S., Bogaerts, J., and Siu, L. L. (2013), “Designing Transformative Clinical Trials in the Cancer Genome Era,” Journal of Clinical Oncology, 31, 1834–1841.
   Google Scholar
• Tang, P. A., Bentzen, S. M., Chen, E. X., and Siu, L. L. (2007), “Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy,” Journal of Clinical Oncology, 25, 4562–4568.
   Google Scholar
• Thall, P. F., Wathen, J. K., Bekele, B. N., Champlin, R. E., Baker, L. H., and Benjamin, R. S. (2003), “Hierarchical Bayesian Approaches to Phase II Trials in Diseases with Multiple Subtypes,” Statistics in Medicine, 22, 763–780.
   Google Scholar
• Wathen, J. K., Thall, P. F., Cook, J. D., and Estey, E. H. (2008), “Accounting for Patient Heterogeneity in Phase II Clinical Trials,” Statistics in Medicine, 27, 2802–2815.
   Google Scholar
• Whitehead, A. (2002), Meta-Analysis of Controlled Clinical Trials, Chichester, UK: Wiley
   Google Scholar